<DOC>
	<DOCNO>NCT00470977</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability intravitreal injection ranibizumab treatment AMD variant choroidal neovascularization ( CNV ) relate condition ( Coats ' disease , idiopathic perifoveal telangiectasia , retinal angiomatous proliferation , polypoidal vasculopathy , pseudoxanthoma elasticum , pathological myopia , multi-focal choroiditis , rubeosis iridis ) use incidence severity adverse event . Limited form treatment available limit loss visual acuity . However , patient may substantial improvement acuity function . Therefore remain significant unmet need therapeutic option manage neovascularization consequence . Lucentis ( ranibizumab ) injection consider attempt control growth abnormal vessel evidence suggest angiogenic factor , vascular endothelial growth factor ( VEGF ) , play role pathogenesis neovascular non-AMD condition . The rationale study design follow : A 0.5 mg dose Lucentis ( ranibizumab ) , commercially available preparation Food Drug Administration ( FDA ) approve labeled intravitreal injection use neovascular ( wet ) age-related macular degeneration use . In AMD variant CNV related condition , vascular endothelial growth factor ( VEGF ) play role pathogenesis neovascular AMD . Intravitreal injection ranibizumab delivers maximal concentration antibody fragment vitreous cavity minimal systemic exposure . The dosing schedule , base consideration half-life clinical response patient neovascularization suggest 1-month interval optimal .</brief_summary>
	<brief_title>Treatment Exudative Vasogenic Chorioretinal Diseases Including Variants AMD Other CNV Related Maculopathy</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Pseudoxanthoma Elasticum</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<mesh_term>Choroiditis</mesh_term>
	<mesh_term>Retinal Telangiectasis</mesh_term>
	<mesh_term>Vitelliform Macular Dystrophy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : 1 . Ability provide write informed consent comply study assessment full duration study 2 . Age &gt; 18 year 3 . Clinical diagnosis follow condition : Coats ' disease , idiopathic perifoveal telangiectasia , retinal angiomatous proliferation , polypoidal vasculopathy , pseudoxanthoma elasticum , pathological myopia , multifocal choroiditis , rubeosis iridis . 4 . Visual acuity 20/40 20/320 study eye ETDRS visual acuity chart . 5 . Media clarity , pupillary dilation patient cooperation sufficient allow OCT test retinal photography Subjects meet follow criterion exclude study : 1 . Any condition investigator believe would pose significant hazard subject investigational therapy initiate 2 . Participation another simultaneous medical investigation trial 3 . Patient significantly compromise visual acuity study eye due concomitant ocular condition . 4 . Patients undergone intraocular surgery within last 2 month . 5 . Patient participate investigational drug study . 6 . Use investigational drug treatment relate unrelated patient 's condition within 30 day prior receipt study medication ( verteporfin , pegaptanib , AMD therapy study eye ) 7 . Patient treat systemic antiVEGF proVEGF agent within 3 month enrollment . 8 . Previous treatment ( either eye ) intravitreal intravenously administer Avastin ( bevacizumab ) . 9 . Inability obtain photographs document CNV ( include difficulty venous access ) . 10 . Patient known adverse reaction fluorescein dye . 11 . Patient history medical condition would preclude schedule visit completion study . 12 . Patient insertion scleral buckle study eye 13 . Patient receive radiation treatment . 14 . Aphakia absence posterior capsule study eye . Previous violation posterior capsule study eye also exclude unless result yttrium aluminum garnet ( YAG ) posterior capsulotomy association posterior chamber lens implantation . 15 . Pregnancy ( positive pregnancy test ) lactation . 16 . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , intrauterine device ( IUD ) , contraceptive hormone implant patch . 17 . History glaucoma filter surgery study eye . 18 . Concurrent use two therapy glaucoma . 19 . Uncontrolled glaucoma study eye ( defined intraocular pressure &gt; 30 mm Hg despite treatment antiglaucoma medication ) 20 . Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>